Intravenous 5-fluoro-2 ′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

ConclusionFurther study of FdCyd + THU is potentially warranted in urothelial carcinoma but not NSCLC or breast or H&N cancer. Increase in the proportion of p16-expressing cytokeratin-positive CTCs is a pharmacodynamic marker of FdCyd target engagement.

http://link.springer.com/10.1007/s00280-020-04073-5

Source: Cancer Chemotherapy and Pharmacology - April 19, 2020 Category: Cancer & Oncology Source Type: research